Endocrine gland-derived vascular endothelial growth factor modulates proliferation, apoptosis and migration in pancreatic cancer cells

• Published in: Molecular medicine reports Vol. 11; no. 6; pp. 4279 - 4284
• Main Authors: REN, LINAN, GUO, XIAOZHONG, SHAO, XIAODONG, LI, HONGYU, YAO, HUI
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.06.2015; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Adult; Aged; Amino acids; Apoptosis; Apoptosis - drug effects; Biosynthesis; Cancer cells; Cancer therapies; Cell growth; Cell Line, Tumor; Cell Movement - drug effects; Cell proliferation; Cell Proliferation - drug effects; Development and progression; endocrine gland-derived vascular endothelial growth factor; Endothelium; Female; Gene Expression; Health aspects; Humans; Immunohistochemistry; Male; Males; MAP kinase; MAP Kinase Signaling System - drug effects; Medical prognosis; Middle Aged; Mortality; Neoplasm Staging; Pancreatic cancer; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - metabolism; Pancreatic Neoplasms - pathology; Phosphorylation; Physiological aspects; proliferation; Protein kinase; Proteins; Studies; Survival factor; Tumor cell lines; Tumors; Vascular endothelial growth factor; Vascular Endothelial Growth Factor, Endocrine-Gland-Derived - genetics; Vascular Endothelial Growth Factor, Endocrine-Gland-Derived - metabolism; Vascular Endothelial Growth Factor, Endocrine-Gland-Derived - pharmacology; China; United States > US
• ISSN: 1791-2997; 1791-3004
• DOI: 10.3892/mmr.2015.3340

Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is a newly cloned factor that selectively acts on the endothelium of endocrine gland cells. EG-VEGF was previously identified as an important cytokine, involved in the modulation of apoptosis in pancreatic cancer cell lines. The present study examined the effects of EG-VEGF proliferation and migration, in pancreatic cancer cells. To determine the potential for EG-VEGF as a therapeutic target for pancreatic cancer, the expression of EG-VEGF were measured in pancreatic cancer tissue, and the association between its expression and the clinicopathological characteristics of the pancreatic cancer patients was determined. The results of the present study suggest that EG-VEGF may act as a novel tumor gene in pancreatic cancer. EG-VEGF was rarely expressed in the normal pancreatic tissue, but was highly expressed in the pancreatic cancer tissue. These data suggest that EG-VEGF may be a cancer-specific, and possibly tissue-specific, survival factor in the pancreas. In the Mia PaCa-2 pancreatic cancer cell line, EG-VEGF was shown to promote proliferation and cellular invasion, and modulate the phosphorylation of mitogen-activated protein kinase, a modulator for the malignant phenotype.